Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, and increased triglyceride levels. Climara Forte should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogens have been identified in the breast milk of women receiving estrogen therapy. Caution should be exercised when the Climara Forte transdermal system is administered to a nursing woman. Pediatric Use Estrogens may be poorly metabolized in women with impaired liver function. For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued. Hypothyroidism Estrogen therapy should be used with caution in women with hypoparathyroidism as estrogen-induced hypocalcemia may occur. Exacerbation Of Endometriosis

Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity. In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted 4. Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately. Climea Forte - suplement diety zawierający izoflawony sojowe, wyciąg z szyszek chmielu, wapń i witaminy, wpływające korzystnie na organizm kobiet w okresie menopauzy. Preparat przeznaczony dla dorosłych kobiet. If your personal data are processed based on your consent, you may withdraw your consent to personal data processing at any time, whereas this will not affect lawfulness of prior processing.Calcium carbonate, soybean extract, bulking agent: cellulose, glazing agent: hydroxypropyl methylcellulose, hop cone extract, glazing agent: magnesium salts of fatty acids, cholecalciferol, ground linseed, bulking agent: sodium carboxymethylcellulose, alpha-crosslinked succinose tocopheryl, dye: titanium dioxide, glazing agent: hydroxypropylcellulose, pyridoxine hydrochloride, pteroylmonoglutamic acid, dyes: quinoline yellow and sunset yellow FCF, glazing agents: beeswax and carnauba wax. Treatment ofbreast cancer(forpalliationonly) in appropriately selected women and men with metastatic disease.

An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in nonusers, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15-to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years). 1 Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of endometrial hyperplasia than would be induced by estrogen treatment alone. Endometrial hyperplasia may be a precursor to endometrial cancer.

After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8. Climara Forte, however, is considerably more potent than estrone and estriol at the estrogen receptor (ER). As a result, the higher estrone concentration in postmenopausal population, can cause various undesirable effects. These effects may include hot flashes, chills, vaginal dryness, mood swings, irregular menstruation, and chills, in addition to sleep problems. After daily administration, the spray formulations of estradiol reach steady state within 7-8 days. After 3 sprays daily, Cmax is about 54 pg/mL with a Tmax of 20 hours. AUC is about 471 pg•hr/mL.Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary. The following adverse reactions have been identified during post-approval use of the Climara Forte transdermal system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System https://www.termedia.pl/Wplyw-zmian-hormonalnych-zachodzacych-w-organizmie-kobiety-na-stan-skory,56,12608,0,0.html Mamy podaną konkretną ilość tych fitohormonów – czyli izoflawonów z nasion soi – na plus – to najważniejszy składnik Climei Forte.

replying to a question/request concerning products, cooperation or business of Aflofarm – the legal basis for processing is your consent or a legitimate interest of the Controller – Article 6(1)(a) and (f) of the GDPR; There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Climara Forte to determine whether those over 65 years of age differ from younger subjects in their response to Climara Forte. The Women’s Health Initiative Studies

Innovators Monograph

Table 1: Treatment-Emergent Adverse Reactions Reported at a Frequency of ≥ 5 Percent and More Frequent in Women Receiving Climara Forte Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med. 2006;166:357-365. Therapy with estrogens should be administered cautiously in patients with preexisting hypertension. In the event that a system should fall off reapply it to a different location. If the system cannot be reapplied, a new system should be applied for the remainder of the 7-day dosing interval. Dose proportionality was also demonstrated for the Climara Forte transdermal system (12.5 cm² and 25 cm²) in a 1-week study conducted in 54 postmenopausal women. The mean steady state levels (Cavg) of the estradiol during the application of Climara Forte 25 cm² and 12.5 cm² on the abdomen were about 80 and 40 pg/mL, respectively.